Regulatory Approvals

FDA Approves Tildrakizumab for Active Psoriatic Arthritis

By

Regulatory Approvals — FDA Approves Tildrakizumab for Active Psoriatic Arthritis  Dermatology Times

Read the original at Regulatory Approvals ↗

Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. October 30, 2026.

By

Related Post

Regulatory Approvals

US FDA approves Inovio’s treatment for rare throat disease; shares surge

Regulatory Approvals

FDA Approves Tildrakizumab for Psoriatic Arthritis in Adults

Regulatory Approvals

October FDA Approvals Bring Advances Across 5 Specialties

Financial News For All

Labor

Why companies offer buyouts versus layoffs

Labor

AI-driven layoffs are creating a new class of boomerang employees—companies are realizing they ‘pulled the plug too quickly’

Regulatory Approvals

FDA Approves First Immunotherapy for Locally Advanced Rectal Cancer

Regulatory Approvals

October FDA Approvals Bring Advances Across 5 Specialties